MOLNZ Stock Overview
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 3.17 |
| 52 Week High | CHF 9.49 |
| 52 Week Low | CHF 2.73 |
| Beta | 0.61 |
| 1 Month Change | -10.21% |
| 3 Month Change | -31.68% |
| 1 Year Change | -3.51% |
| 3 Year Change | -80.58% |
| 5 Year Change | n/a |
| Change since IPO | -83.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOLNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.6% | 1.1% | 4.7% |
| 1Y | -3.5% | -17.7% | 2.3% |
Return vs Industry: MOLNZ exceeded the UK Biotechs industry which returned -17.7% over the past year.
Return vs Market: MOLNZ underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| MOLNZ volatility | |
|---|---|
| MOLNZ Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: MOLNZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: MOLNZ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 159 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.
Molecular Partners AG Fundamentals Summary
| MOLNZ fundamental statistics | |
|---|---|
| Market cap | CHF 116.52m |
| Earnings (TTM) | -CHF 54.04m |
| Revenue (TTM) | CHF 4.97m |
23.4x
P/S Ratio-2.2x
P/E RatioIs MOLNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 4.97m |
| Cost of Revenue | CHF 47.50m |
| Gross Profit | -CHF 42.53m |
| Other Expenses | CHF 11.51m |
| Earnings | -CHF 54.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 25, 2025
| Earnings per share (EPS) | -1.47 |
| Gross Margin | -855.81% |
| Net Profit Margin | -1,087.38% |
| Debt/Equity Ratio | 0% |
How did MOLNZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 03:19 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecular Partners AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jo Walton | Credit Suisse |
| null null | Credit Suisse |
| Thomas Kaufmann | Credit Suisse |